DTX in combination with anti–PD-1 failed to inhibit tumor growth, and all tumors treated with vehicle or DTX in combination with anti–PD-1 reached the ethical endpoint within 25 days (Figure 6G and Supplemental Figure 6D). Here, PDCD1 is linked to neoplasm.